Table 4.
Association of incident CKD stage 3 with quartile of log urinary CTGF in the Framingham Heart Study and ARIC Study
| OR (95% CI) | P-value for trend | |||
|---|---|---|---|---|
| Q2 vs. Q1 | Q3 vs. Q1 | Q4 vs. Q1 | ||
| Framingham Heart Study | ||||
| Overall sample | ||||
| Unadjusted | 0.44 (0.19–1.04) | 0.10 (0.03–0.35) | 0.10 (0.03–0.32) | <.0001 |
| multivariable-adjusted* | 0.56 (0.25–1.28) | 0.13 (0.04–0.37) | 0.06 (0.02–0.20) | <.0001 |
| multivariable-adjusted* + UACR | 0.54 (0.23–1.24) | 0.13 (0.04–0.38) | 0.06 (0.02–0.20) | <.0001 |
| Non-Diabetes sample | ||||
| Unadjusted | 0.66(0.32–1.37) | 0.16(0.06–0.42) | 0.11(0.04–0.33) | <.0001 |
| multivariable-adjusted* | 0.55(0.24–1.30) | 0.13(0.04–0.40) | 0.06(0.02–0.22) | <.0001 |
| multivariable-adjusted* + UACR | 0.57(0.24–1.36) | 0.14(0.05–0.42) | 0.06(0.02–0.23) | <.0001 |
| ARIC | ||||
| Overall sample | ||||
| Unadjusted | 1.05 (0.56–2.00) | 0.44 (0.21–0.91) | 0.60 (0.28–1.26) | 0.04 |
| multivariable-adjusted* | 1.09 (0.56–2.12) | 0.45 (0.21–0.97) | 0.74 (0.34–1.61) | 0.1 |
| multivariable-adjusted* + UACR | 1.09 (0.56–2.13) | 0.45 (0.21–0.97) | 0.74 (0.34–1.61) | 0.1 |
| Non-Diabetes sample | ||||
| Unadjusted | 1.16 (0.57–2.37) | 0.37 (0.16–0.84) | 0.57 (0.25–1.30) | 0.03 |
| multivariable-adjusted* | 1.23 (0.58–2.63) | 0.34 (0.14–0.84) | 0.70 (0.29–1.67) | 0.07 |
| multivariable-adjusted* + UACR | 1.23 (0.57–2.64) | 0.34 (0.14–0.84) | 0.70 (0.29–1.67) | 0.07 |
Odds ratio of CKD by quartiles of urinary CTGF concentration in the Framingham Heart Study and ARI
*
Multivariable adjustment included the following variables: estimated glomerular filtration rate, systolic blood pressure, hypertension treatment, diabetes, high density lipoprotein-cholesterol, body mass index, smoking
Abbreviation: UACR: Urinary albumin-creatinine ratio; ARIC, Atherosclerosis Risk in Communities; CTGF, connective tissue growth factor; CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval